"Clofazimine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
Concept/Terms
Clofazimine- Clofazimine
- N,5-Bis(4-chlorophenyl)-3,5-dihydro-3-((1-methylethyl)imino)-2-phenazinamine
Below are MeSH descriptors whose meaning is more general than "Clofazimine".
Below are MeSH descriptors whose meaning is more specific than "Clofazimine".
This graph shows the total number of publications written about "Clofazimine" by people in Harvard Catalyst Profiles by year, and whether "Clofazimine" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 2 | 0 | 2 |
2004 | 0 | 1 | 1 |
2005 | 1 | 0 | 1 |
2012 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2014 | 1 | 0 | 1 |
2018 | 1 | 1 | 2 |
2020 | 0 | 1 | 1 |
2021 | 0 | 1 | 1 |
2022 | 2 | 0 | 2 |
2023 | 0 | 2 | 2 |
Below are the most recent publications written about "Clofazimine" by people in Profiles.
-
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial. Trials. 2023 Nov 30; 24(1):773.
-
Clofazimine nanoclusters show high efficacy in experimental TB with amelioration in paradoxical lung inflammation. Biomater Adv. 2023 Nov; 154:213594.
-
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2023 06 01; 207(11):1525-1532.
-
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs. Clin Infect Dis. 2022 Oct 12; 75(8):1307-1314.
-
Clofazimine for Babesiosis: Preclinical Data Support a Clinical Trial. J Infect Dis. 2022 01 18; 225(2):187-189.
-
Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex. Antimicrob Agents Chemother. 2021 10 18; 65(11):e0116421.
-
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother. 2020 08 01; 75(8):2031-2043.
-
Clofazimine for the treatment of multidrug-resistant tuberculosis. Clin Microbiol Infect. 2019 02; 25(2):128-130.
-
Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma. J Clin Invest. 2018 10 01; 128(10):4682-4696.
-
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 09 08; 392(10150):821-834.